Dyne Therapeutics, a Waltham, Massachusetts, biopharmaceutical company, announced yesterday that it is accelerating its FSHD therapy development program. Here is their press release: Dyne to evaluate therapies targeting genetic cause […]
Dyne ramps up its FSHD program
Recent FSHD research publications
[…] of DUX4, which is very important to understand if we are to attempt to treat FSHD by suppressing the unwanted negative effects of DUX4. * “Antisense Oligonucleotides Used to Target […]
BetterLife FSHD
A health & research platform providing tools to better understand and manage your FSHD Join BetterLife FSHD today! Join Here About BetterLife FSHD BetterLife FSHD is a pioneering research platform […]
Q &A on potential use of BET inhibitors for FSHD
On February 13, Canadian biotech, Reserverlogix announced that facioscapulohumeral muscular dystrophy ( FSHD) is one of two new indications it is pursuing involving its lead drug, apabetalone (RVX-208) which inhibits […]
FSHD Gene May Help Tumors Evade the Immune System
[…] MONS, BELGIUM DUX4, the gene that plays a key role in facioscapulohumeral muscular dystrophy ( FSHD), is gaining unexpected notoriety in cancer research. According to a recent study1 from the […]